RESUMO
Although the European Union merely followed the initiatives of the United States and Japan by introducing special regimes for orphan medicinal products, it has introduced a special status for a new category of biological medicinal products, advanced therapy medicinal products (ATMPs), adopting specific associated regulations. European Regulation (which constitutes the highest legal instrument in the hierarchy of European law texts) [EC] No. 1394/2007, published in 2007, uses this term to define somatic cell therapy medicinal products, tissue-engineered products, and gene therapy medicinal products, possibly combined with medical devices. The stated objective was two-fold: both to promote their industrialization and market access, while guaranteeing a high level of health protection for patients. Since publication of the regulation, few marketing authorizations have been granted in Europe, and these have not been accompanied by commercial success. However, certain recent studies show that this is a growing sector and that France remains the leading European nation in terms of clinical trials. This round table brought together a panel of representatives of French public and private protagonists from the advanced therapy sector. The discussions focused on the conditions to ensure the success of translational research and, more generally, the French advanced therapy sector. These enabled a number of obstacles to be identified, which once lifted, by means of recommendations, would facilitate the development and success of this sector.
Assuntos
Produtos Biológicos , Pesquisa Biomédica/tendências , Produtos Biológicos/classificação , Pesquisa Biomédica/legislação & jurisprudência , Terapia Baseada em Transplante de Células e Tecidos , Certificação/legislação & jurisprudência , Ensaios Clínicos como Assunto/legislação & jurisprudência , União Europeia , França , Terapia Genética/legislação & jurisprudência , Política de Saúde , Humanos , Invenções/economia , Invenções/tendências , Indústria Manufatureira/economia , Indústria Manufatureira/legislação & jurisprudência , Indústria Manufatureira/organização & administração , Organismos Geneticamente Modificados , Produção de Droga sem Interesse Comercial/legislação & jurisprudência , Engenharia Tecidual/legislação & jurisprudência , Universidades/legislação & jurisprudênciaRESUMO
Recent drug crises have highlighted the complexity, benefits and risks of medication communication. The difficulty of this communication is due to the diversity of the sources of information and the target audience, the credibility of spokespersons, the difficulty to communicate on scientific uncertainties and the precautionary principle, which is influenced by variable perceptions and tolerances of the risk. Globally, there is a lack of training in risk management with a tendency of modern society to refuse even the slightest risk. Communication on medications is subject to regulatory or legal requirements, often uses tools and messages that are not adapted to the target audience and is often based on a poor knowledge of communication techniques. In order to improve this situation, the available information must be coordinated by reinforcing the unique medication information website and by coordinating communication between authorities by means of a single spokesperson. A particular effort must be made in the field of training in the proper use and risk of medications for both the general population and patients but also for healthcare professionals, by setting up a unified academic on-line teaching platform for continuing medical education on medications and their proper use.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Educação em Saúde , Pessoal de Saúde/educação , Disseminação de Informação , Barreiras de Comunicação , Bases de Dados Factuais , Serviços de Informação sobre Medicamentos , Educação Médica Continuada , Guias como Assunto , Necessidades e Demandas de Serviços de Saúde , Humanos , Prescrição Inadequada/prevenção & controle , Comportamento de Busca de Informação , Gestão de Riscos , Comportamento de Redução do Risco , Revelação da VerdadeRESUMO
The development of medicinal products is subject to quality standards aimed at guaranteeing that database contents accurately reflect the source documents. Paradoxically, these standards hardly address the quality of the source data itself. The objective of this work was to propose recommendations to improve data quality in three fields (pharmacovigilance, pharmacoepidemiology and clinical studies). The analysis was focused on the data and on the critical stages presenting critical quality problems, for which the current guidelines are insufficiently detailed, unsuitable and/or poorly applied. Finally, recommendations have been proposed, mainly focused on the origin of the data and its transcription.